Literature DB >> 8825117

Recombinant immunotoxins.

I Pastan1, L H Pai, U Brinkmann, D FitzGerald.   

Abstract

Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825117     DOI: 10.1007/BF01803778

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.624


  25 in total

Review 1.  Possible functions of tumor-associated carbohydrate antigens.

Authors:  S Hakomori
Journal:  Curr Opin Immunol       Date:  1991-10       Impact factor: 7.486

2.  PR1--a monoclonal antibody that reacts with an antigen on the surface of normal and malignant prostate cells.

Authors:  I Pastan; E Lovelace; A V Rutherford; S Kunwar; M C Willingham; D M Peehl
Journal:  J Natl Cancer Inst       Date:  1993-07-21       Impact factor: 13.506

3.  Expression of an altered epidermal growth factor receptor by human glioblastoma cells.

Authors:  P A Steck; P Lee; M C Hung; W K Yung
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

Review 4.  Molecular manipulations of the multidrug transporter: a new role for transgenic mice.

Authors:  I Pastan; M C Willingham; M Gottesman
Journal:  FASEB J       Date:  1991-08       Impact factor: 5.191

5.  The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A.

Authors:  M Z Kounnas; R E Morris; M R Thompson; D J FitzGerald; D K Strickland; C B Saelinger
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.486

6.  Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.

Authors:  V S Allured; R J Collier; S F Carroll; D B McKay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 12.779

Review 7.  Immunotoxin therapy for cancer.

Authors:  L H Pai; I Pastan
Journal:  JAMA       Date:  1993-01-06       Impact factor: 157.335

8.  A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies.

Authors:  J Buchner; I Pastan; U Brinkmann
Journal:  Anal Biochem       Date:  1992-09       Impact factor: 3.191

9.  B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

Authors:  U Brinkmann; L H Pai; D J FitzGerald; M Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 12.779

10.  Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver.

Authors:  M F Chiron; C M Fryling; D J FitzGerald
Journal:  J Biol Chem       Date:  1994-07-08       Impact factor: 5.486

View more
  3 in total

1.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen.

Authors:  M Papetti; I M Herman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens.

Authors:  M D Sheets; P Amersdorfer; R Finnern; P Sargent; E Lindquist; R Schier; G Hemingsen; C Wong; J C Gerhart; J D Marks; E Lindqvist
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Targeting oncogenic Ras by the Clostridium perfringens toxin TpeL.

Authors:  Björn Schorch; Hannah Heni; Nour-Imene Zahaf; Tilman Brummer; Marina Mione; Gudula Schmidt; Panagiotis Papatheodorou; Klaus Aktories
Journal:  Oncotarget       Date:  2018-03-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.